🇺🇸 Levodopa/carbidopa/entacapone in United States

161 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fall — 23 reports (14.29%)
  2. Drug Ineffective — 21 reports (13.04%)
  3. Dyskinesia — 21 reports (13.04%)
  4. Parkinson^S Disease — 20 reports (12.42%)
  5. Hallucination, Visual — 14 reports (8.7%)
  6. Gait Disturbance — 13 reports (8.07%)
  7. Weight Decreased — 13 reports (8.07%)
  8. Mobility Decreased — 12 reports (7.45%)
  9. On And Off Phenomenon — 12 reports (7.45%)
  10. Pneumonia — 12 reports (7.45%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is Levodopa/carbidopa/entacapone approved in United States?

Levodopa/carbidopa/entacapone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Levodopa/carbidopa/entacapone in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.